SCHEMBL4092770

SCHEMBL4092770

CN(CCCN1CCC(c2ccccc2)(N(C)C)CC1)C(=O)CCc1c[nH]c2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
CDK4 P11802 2/20 0.55
MC5R P33032 3/20 0.51
MC4R P32245 2/20 0.51
MC3R P41968 2/20 0.51
OPRL1 P41146 6/20 0.51
TACR2 P21452 4/20 0.51
OPRM1 P35372 4/20 0.50
HTR1A P08908 2/20 0.49
CCND1 P24385 1/20 0.47
DRD2 P14416 1/20 0.46
DRD4 P21917 1/20 0.46
HTR2A P28223 1/20 0.46
SLC6A4 P31645 1/20 0.46
HRH1 P35367 1/20 0.46
DRD3 P35462 1/20 0.46
HTR2B P41595 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3405562 0.94 CDK4 (0.57) NPC1SMN1; SMN2CDK4MC5RMC4R
SCHEMBL3406318 0.88 SMN1; SMN2 (0.51) NPC1SMN1; SMN2CDK4MC5RMC4R
SCHEMBL3409873 0.83 OPRL1 (0.42) NPC1SMN1; SMN2MC5RMC4RMC3R
SCHEMBL3406143 0.82 HSD17B10 (0.46) SMN1; SMN2OPRM1DRD2DRD4DRD3
SCHEMBL3409859 0.82 OPRL1 (0.41) NPC1SMN1; SMN2MC5RMC4RMC3R
SCHEMBL3405510 0.81 OPRM1 (0.43) OPRL1TACR2OPRM1HTR1ADRD2
SCHEMBL3409909 0.81 HTR1A (0.48) OPRL1TACR2OPRM1HTR1ADRD2
SCHEMBL4103472 0.80 SMN1; SMN2 (0.59) NPC1SMN1; SMN2CDK4MC5RMC4R
SCHEMBL3410692 0.78 OPRL1 (0.65) OPRL1OPRM1HTR1ADRD2DRD4
SCHEMBL3409649 0.78 CDK4 (0.46) CDK4OPRL1TACR2OPRM1CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206156-B2 Substituted indole derivatives Grünenthal GmbH (DE) 2015-12-08 US claimed
EP-2254883-B1 SUBSTITUTED INDOLE DERIVATIVES GRUENENTHAL GMBH (DE) 2014-11-26 EP claimed
US-20130116283-A1 Substituted indole derivatives Grünenthal GmbH (DE) 2013-05-09 US claimed
US-20090215828-A1 Substituted indole derivatives GRUNENTHAL GMBH (DE) 2009-08-27 US claimed
US-9206156-B2 Substituted indole derivatives Grünenthal GmbH (DE) 2015-12-08 US disclosed
US-9206156-B2 Substituted indole derivatives Grünenthal GmbH (DE) 2015-12-08 US disclosed
EP-2254883-B1 SUBSTITUTED INDOLE DERIVATIVES GRUENENTHAL GMBH (DE) 2014-11-26 EP disclosed
EP-2254883-B1 SUBSTITUTED INDOLE DERIVATIVES GRUENENTHAL GMBH (DE) 2014-11-26 EP disclosed
US-20130116283-A1 Substituted indole derivatives Grünenthal GmbH (DE) 2013-05-09 US disclosed
US-20130116283-A1 Substituted indole derivatives Grünenthal GmbH (DE) 2013-05-09 US disclosed
WO-2009103552-A1 SUBSTITUTED INDOLE DERIVATIVES Grünenthal GmbH (DE) 2009-08-27 WO disclosed
US-20090215828-A1 Substituted indole derivatives GRUNENTHAL GMBH (DE) 2009-08-27 US disclosed
US-20090215828-A1 Substituted indole derivatives GRUNENTHAL GMBH (DE) 2009-08-27 US disclosed
US-20090215828-A1 Substituted indole derivatives GRUNENTHAL GMBH (DE) 2009-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215828-A1 Substituted indole derivatives IDO1, IDO2, TPH1 NPC1 1353/4885SMN1; SMN2 1803/4885CDK4 1411/4885
US-20130116283-A1 Substituted indole derivatives IDO1, IDO2, TPH1 NPC1 1353/4885SMN1; SMN2 1803/4885CDK4 1411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.